NCT03392311View on ClinicalTrials.gov

Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

October 23, 2019

Study Completion Date

March 19, 2020

Conditions
Mesenchymal Stromal CellsPsoriasisDrug EffectDrug Toxicity
Interventions
DRUG

Calcipotriol ointment

The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.

BIOLOGICAL

adipose-derived multipotent mesenchymal stem cells

AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.

Trial Locations (1)

Unknown

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial Hospital of Traditional Chinese Medicine

OTHER

NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter